Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11 Mln
P/E Ratio
--
P/B Ratio
3.76
Industry P/E
--
Debt to Equity
-0.38
ROE
-5.23 %
ROCE
944.2 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-150.88 Mln
EBITDA
$-153.19 Mln
Net Profit
$-184.05 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
PLUS THERAPEUTICS (PSTV)
| -31.57 | -33.31 | -36.53 | -51.72 | -60.96 | -48.86 | -69.64 |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
PLUS THERAPEUTICS (PSTV)
| -34.06 | -63.20 | -69.52 | -48.02 | -15.83 | -83.45 | -90.26 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.48 | 9,808.03 | 20.22 | 23.13 | |
| 282.28 | 8,956.09 | 22.08 | 58.42 | |
| 25.74 | 9,559.25 | -- | -28.77 | |
| 101.74 | 10,030.35 | 30.81 | 14.16 |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic drug candidate is REYOBIQ, a patented... radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Address: 2710 Reed Road, Austin, TX, United States, 77051 Read more
President, CEO & Director
Dr. Marc H. Hedrick M.B.A., M.D.
President, CEO & Director
Dr. Marc H. Hedrick M.B.A., M.D.
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of PLUS THERAPEUTICS Inc (PSTV) stood at $ 7 Mln as on 31-Dec-24
The share price of PLUS THERAPEUTICS Inc (PSTV) is $0.79 (NASDAQ) as of 22-Apr-2025 16:28 EDT. PLUS THERAPEUTICS Inc (PSTV) has given a return of -60.96% in the last 3 years.
PLUS THERAPEUTICS Inc (PSTV) has a market capitalisation of $ 11 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of PLUS THERAPEUTICS Inc (PSTV) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the PLUS THERAPEUTICS Inc (PSTV) and enter the required number of quantities and click on buy to purchase the shares of PLUS THERAPEUTICS Inc (PSTV).
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic drug candidate is REYOBIQ, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Address: 2710 Reed Road, Austin, TX, United States, 77051
The CEO & director of Dr. Marc H. Hedrick M.B.A., M.D.. is PLUS THERAPEUTICS Inc (PSTV), and CFO & Sr. VP is Dr. Marc H. Hedrick M.B.A., M.D..
There is no promoter pledging in PLUS THERAPEUTICS Inc (PSTV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| PLUS THERAPEUTICS Inc. (PSTV) | Ratios |
|---|---|
|
Return on equity(%)
|
252.07
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of PLUS THERAPEUTICS Inc (PSTV) was $0 Mln.
$0.15
(
